TY - JOUR T1 - Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis–associated Uveitis JF - The Journal of Rheumatology JO - J Rheumatol SP - 260 LP - 261 DO - 10.3899/jrheum.160908 VL - 44 IS - 2 AU - ESTEFANIA QUESADA-MASACHS AU - CONSUELO MODESTO CABALLERO Y1 - 2017/02/01 UR - http://www.jrheum.org/content/44/2/260.abstract N2 - To the Editor:Tocilizumab (TCZ) is a fully humanized, monoclonal, anti-interleukin-6R antibody shown by clinical trials to be a safe and effective treatment for patients with rheumatoid arthritis (RA) or systemic-onset or polyarticular juvenile idiopathic arthritis (JIA)1,2,3. TCZ seems to be an effective agent to treat JIA-associated uveitis, and several case reports have described a good efficacy profile in patients with refractory JIA-associated uveitis4,5. Interim outcomes of the STOP-Uveitis clinical trial were presented by Nguyen, et al, showing that TCZ has a good safety and efficacy profile in noninfectious uveitis6. For several years, TCZ has also been available in a subcutaneous (SC) formulation, and switching from intravenous (IV) to SC administration may provide greater flexibility and quality of life to patients who follow TCZ treatment. Several clinical trials have shown the safety and efficacy profile of TCZ-SC to be comparable to that of TCZ-IV7. Switching from TCZ-IV to SC was shown to be … Address correspondence to Dr. C. Modesto Caballero, Hospital Universitario Vall d’Hebron, Unidad de Reumatología (Módulo C), Paseo de la Vall d’Hebron 119-129, 08035, Barcelona, Spain. E-mail: cmodesto{at}vhebron.net ER -